
    
      Follow-up of participants should enable three visits during this period. At the Screening
      Visit the decision for Klacid SR therapy in a dose of 500 -1000 mg once daily will be made.
      The Second Visit will occur 8 - 16 days after study initiation. The Last Visit will be a
      phone call to the participant after 30 days from the initiation of the treatment. Study
      visits will be defined as "V1" = Screening Visit, "V2" = Visit in which Klacid SR therapy
      will be terminated and "V3" = Phone call 30 days after initiation of Klacid SR therapy.
    
  